Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
non-Hodgkin lymphoma
Pharma
BeOne's Venclexta challenger Beqalzi nets FDA approval
MCL is BeOne’s stepping stone to potentially reshape the broader BCL-2 landscape, which is presently dominated by AbbVie and Roche’s Venclexta.
Angus Liu
May 13, 2026 4:45pm
BMS lauds Breyanzi's shutout against cancer with soccer legend
Feb 4, 2026 12:25pm
Incyte to seek FDA approval for Monjuvi in front-line DLBCL
Jan 5, 2026 10:40am
Roche’s bispecific-ADC combo keeps lymphoma at bay
Jun 23, 2025 10:27am
BMS angles Breyanzi for another blood cancer
Feb 10, 2025 9:50am
FDA approves Citius' Lymphir for cutaneous T-cell lymphoma
Aug 8, 2024 11:21am
